The aim of the European Journal of Nuclear Medicine and Molecular Imaging is to provide a forum for the exchange of clinical and scientific information for the imaging community and allied professions involved in the functional, metabolic and molecular investigation of diseases. The European Journal of Nuclear Medicine and Molecular Imaging will remain of primary interest to those practicing the field of imaging, radiopharmaceutical therapy and image guided therapy. The field of interest includes advanced imaging analyses techniques and artificial intelligence application in the field of imaging. Reports on original works related to physics, dosimetry, radiation biology, radiochemistry and pharmacy, will be considered in the field of interest of the EJNMMI. The Journal will welcome original material reflecting the field of molecular imaging probes, reporter gene assays, cell trafficking, targeting of endogenous gene expression and antisense methodologies.

The Journal will continue to publish in depth Reviews of topical interest, Short communications, Controversies, interesting images and Letters to the editor. Case reports are not published.

The journal publishes the following article types:

Original article,

Review article,

Letter to the Editor,

Guidelines,

Controversies,

Image of the month,

Short Communications,

Editorials

《欧洲核医学与分子成像杂志》旨在为影像界和相关专业提供一个交流临床和科学信息的论坛，这些专业涉及疾病的功能、代谢和分子研究。《欧洲核医学与分子成像杂志》仍将主要吸引那些从事成像、放射性药物治疗和图像引导治疗领域的人士。该领域包括先进的成像分析技术和人工智能在成像领域的应用。与物理学、剂量测定、放射生物学、放射化学和药学相关的原创作品报告将被纳入 EJNMMI 的关注领域。该杂志将欢迎反映分子成像探针、报告基因检测、细胞运输、内源性基因表达靶向和反义方法领域的原创材料。

该杂志将继续发表深度专题评论、简短通讯、争议、有趣的图像和致编辑的信。病例报告不发表。

本期刊发表以下类型的文章：

原创文章，

评论文章，

致编辑的信，

指南，

争议，

本月图片，

简短通讯，

社论

该刊已被国际权威数据库SCIE收录，是国际顶级期刊。该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-核医学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为8.6，平均审稿速度为 约3月 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。